Urinary nucleosides in leukemia: laboratory and clinical applications.
Urinary nucleosides offer a number of useful laboratory and clinical applications in the study and analysis of leukemia. There are significant differences in the excretion of modified nucleosides between normal individuals and individuals with various forms of leukemia, as well as between leukemia patients at opposite ends of the clinical spectrum, i.e., those with active disease and those in remission. The nucleoside excretion levels correlate to bone marrow tumor burden in certain forms of leukemia, and limited serial data indicate the potential value of the nucleosides for predicting relapse before the disease deterioration can be recognized clinically. In addition, it may be feasible to assess the effectiveness of chemotherapy used in the treatment of leukemia much more rapidly with the urinary nucleoside markers than with conventional invasive methods.
D000208:Acute Disease; D000328:Adult; D001896:Boron Compounds; D002648:Child; D002675:Child, Preschool; D002851:Chromatography, High Pressure Liquid; D002908:Chronic Disease; D006801:Humans; D007118:Immunoassay; D007938:Leukemia / Q000652:urine*; D007945:Leukemia, Lymphoid / Q000652:urine; D007951:Leukemia, Myeloid / Q000652:urine; D009705:Nucleosides / Q000302:isolation & purification / Q000652:urine*; D012016:Reference Values
D001896:Boron Compounds; D009705:Nucleosides